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I
n 2002 cancer accounted for 16.7% 
of the total burden of disease in the 
European Union (EU), compared 
with 25.3% and 17.1% for mental health 
and cardiovascular diseases, respectively 
[1]. In the period relevant to this Policy 
Forum, cancer was the second largest 
cause of mortality in the EU, accounting 
for 27.08% of all deaths. With the 
ageing population and the continuing 
impact of tobacco-associated cancers, 
it is predicted that cancer rates could 
increase by 50% to 15 million new cases 
worldwide in the year 2020 [1].
A recent update of cancer incidence 
and mortality for the EU in 2004 by 
the International Agency for Research 
on Cancer estimated 2,886,800 
incident cases of cancer diagnosed 
and 1,711,000 cancer deaths [2]. As 
the authors of the update note, “the 
ageing of the European population 
will cause these numbers to continue 
to increase even if age-speciﬁ  c rates 
remain constant.” Furthermore, despite 
substantial progress through public 
health measures (i.e., tobacco control) 
and new treatments, survival is still poor 
for many cancers, such as lung cancer. 
These ﬁ  gures speak for themselves in 
making the case for a substantial and 
sustained European approach to cancer 
through public health measures and 
research. 
The Case for European Cancer 
Research
Europe needs both a strong commercial 
and a publicly funded (noncommercial) 
research base. In this article, we report 
the results of the European Cancer 
Research Funding Survey, which looked 
at noncommercial, public funding of 
cancer research. This survey has, for 
the ﬁ  rst time, recognised the essential 
contribution that governments, 
charities, and European organisations 
make towards funding the broad 
church of research to ﬁ  nd new ways to 
control and cure cancer. This funding, 
focused on the needs of patients with 
cancer rather than the commercial 
or economic advantage, is essential 
to deliver the myriad of solutions that 
cancer demands, from new strategies 
to prevent cancer, to therapies and 
improvements in patients’ quality of life. 
The public support of cancer 
research permits the necessary 
degree of variety and ﬂ  exibility that is 
essential to preserving the diversity of 
cancer research [3]. This diversity in 
turn keeps the research possibilities 
sufﬁ  ciently open to ensure that no 
good idea or discovery is lost. In order 
to support better evidence-based 
policy making in this important area, 
we undertook a pan-EU survey of 
the major public funders of cancer 
research. 
Our Survey Methods
Between July and December 2003, 
we sent letters to each of the general 
members of the European Cancer 
Research Managers Forum (ECRM; 
see http:⁄⁄www.ecrmforum.org), 
asking them to identify the sources 
of cancer research funding within 
their countries’ boundaries. After 
the ECRM members had created an 
initial database of funding bodies for 
all countries within the EU, accession 
countries, and European free trade 
area (EFTA) associate and applicant 
states, all identiﬁ  ed cancer research 
funding organisations were directly 
contacted. These funding bodies 
were asked to (1) provide their latest 
available ﬁ  gures for annual spending 
on direct cancer research, (2) provide 
a list of executive/board members, 
and (3) classify themselves as either 
governmental or charity organisations 
according to the enclosed guidelines. 
We also asked respondents to report 
their annual spending on cancer 
research according to the seven main 
classiﬁ  cations of the common scientiﬁ  c 
outline (CSO), a classiﬁ  cation system 
organised around seven broad areas 
of scientiﬁ  c interest in cancer research 
(http:⁄⁄researchportfolio.cancer.gov/
cso.html; Box 1). We chose to quantify 
annual spending by CSO because of 
its ability to compare and contrast 
research portfolios of public, nonproﬁ  t, 
and governmental research agencies 
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Box 1. The Seven Components 
of the CSO 
• Biology 
•  Etiology (causes of disease) 
• Prevention 
•  Early detection, diagnosis, and 
prognosis 
• Treatment 
•  Cancer control, survivorship, and 
outcomes research 
• Scientiﬁ  c model systems (e.g., 
computer simulation, cell culture, and 
organ, tissue, and animal models)
(Data from http://researchportfolio.
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using a validated and controlled 
vocabulary. Finally, respondents 
were provided with a list of all other 
identiﬁ  ed funding bodies within 
their country for cross-validation. If a 
respondent organisation had a Web 
site, we examined the Web site for 
ﬁ  nancial information, which we cross-
referenced with the self-reported data. 
All information received and gathered 
was entered into an Access database.
At the beginning of the survey, 
guidelines were established to help with 
this quantiﬁ  cation, and were followed 
through the data collection and data 
entry phases. If a funding organisation 
reported a range of spending on cancer 
research between two values, we always 
used the higher amount. In evaluating 
annual direct cancer research 
spending, we excluded educational 
grants, non–research staff salaries 
(other than research managers), 
physical plant improvements, and 
spending on advocacy and service 
delivery. CSO categories were only 
entered into the database if they were 
provided as a percent or monetary unit 
of the total spending. Any organization 
reporting spending in currencies 
other than the Euro had the reported 
amount of spending converted into 
Euros using the following Web site, 
http:⁄⁄www.xe.com; for replies received 
on or before 15 May 2004, conversions 
were made on that date. After this date, 
all currencies were converted within 
two days of receipt of the information. 
Calculations such as gross domestic 
product (GDP) and GDP per capita 
were then made using ColdfusionMX 
(http:⁄⁄www.macromedia.com/
software/coldfusion), and were veriﬁ  ed 
with Microsoft Excel, based upon data 
groomed from multiple sources.
At the end of the data collection 
phase of the survey, 123 of 139 
identiﬁ  ed funding organisations had 
reported back to the Secretariat, 
exceeding the 85% response rate set at 
the beginning of the survey to consider 
the work complete. One organization 
refused to provide any information 
other than contact details, and one 
other reported that there was no 
ﬁ  nancial information publicly available. 
Finally, we compared data from our 
EU survey with data on cancer research 
spending in the United States published 
by the US National Cancer Institute.
Survey Results
National variations in spending. 
In our survey, we identiﬁ  ed 139 
noncommercial funding organisations 
that collectively spent  1.43 billion on 
cancer research for the year spanning 
2002–2003. Absolute spending in 
2002/2003 on cancer research varied 
widely across the EU, ranging from 
 388 million in the United Kingdom 
to  0 in Malta, with three countries 
spending greater than  100 million, 
nine greater than  10 million, and 
ten less than  1 million. Of all the 
countries in the survey, only Bulgaria 
failed to report their spending, and 
only Malta spent nothing on cancer 
research in 2002/2003 (Figure 1).
Spending by CSO in the EU and the 
US. The EU spends a greater proportion 
of its cancer research funding on 
cancer biology than does the US (41% 
compared with 25%). The US spends a 
greater proportion of its cancer research 
funding on research into prevention 
and treatment than does the EU 
(prevention, 9% in the US compared 
with 4% in the EU; treatment, 25% in 
the US compared with 20% in the EU) 
(Figure 2). Data published by the US 
National Cancer Institute has been fully 
validated, whereas the EU uses self-
reported, top-level CSO categories for 
62% (n = 74) of the organisations from 
which ﬁ  nancial data was obtained. The 
size of the two pie charts in Figure 2 is 
representative of the sizes of the annual 
budgets: in 2002/2003, the US National 
Cancer Institute spent  3.60 billion, 
compared with the EU spending of 
 1.43 billion.
Spending by charities versus 
governments. Our survey showed 
that just over 50% of noncommercial 
funding in the EU (including EFTA 
and associate states) is provided 
by the charitable sector, with 65 
major charities across 23 countries 
contributing around  667.3 
million to cancer research (Figure 
3). In comparison, there are 74 
governmental sources of cancer 
research funding, spread across 28 
countries, with a reported spending 
of  662.3 million in 2002/2003. It 
DOI: 10.1371/journal.pmed.0030267.g001
Figure 1. Direct Cancer Research Spending by Country, including European Commission and 
Trans-European Organisations
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should be noted that these ﬁ  gures 
do not include contributions from 
organisations not contained within 
member state boundaries (Trans-
European Organisations) and the EU 
Commission spending for 2002/2003.
For charities, the average amount 
spent per charity was  21.5 million, and 
the median spending was  400,000. 
Among governmental agencies, the 
average spent was  21.4 million, 
and their median spending was  1.9 
million. In eight countries, there was no 
cancer research spending by charitable 
organisations, while in three countries, 
there was no spending by governments. 
In 11 countries, charities spent more on 
cancer research than did governments.
Of the 31 countries involved in this 
survey, six had more charities than 
governmental agencies, with ten having 
the same number for both types of 
funding organisations. The average 
number of charities per country 
was 2.1, and the average number of 
governmental agencies was 2.4.
Spending by political grouping. 
Current member states (n = 25) 
contributed  1.30 billion annually to 
noncommercial cancer research; the 
accession countries contributed only 
 21.3 million in 2002/2003, which 
was just 2% of the total annual amount 
(Figure 4). The European Commission 
contributed  90 million, or just over 
6%, of the identiﬁ  ed total direct cancer 
research spending. However, this 
number is likely an underestimation, as 
cancer research is being supported by 
other, nondirect funding streams from 
the commission. However, to put this 
in perspective, the EU spends over  1 
billion on tobacco subsidies every year.
Total spending by the EU versus the 
US. The average per capita spent across 
the entire EU (including European 
Commission and Trans-European 
Organisation spending) was  2.56 
(US$3.30), while the per capita spent 
in the US was  17.63 (US$22.76)—
seven times greater. This gap is 
reduced to 5-fold if the US spending 
is compared with the spending of 
the 15 EU countries only (Figure 5). 
Average cancer research spending as a 
percentage of GDP across the EU was 
0.0152%, and the median was 0.0056%. 
As a percentage of GDP, the US spent 
four times as much as the average 
across the entire European survey; this 
difference remained the same when 
the US percentage was compared with 
DOI: 10.1371/journal.pmed.0030267.g002
Figure 2. Percentage Spending by CSO: EU versus US
The relative sizes of the two pie charts are proportional to the sizes of the two budgets.
DOI: 10.1371/journal.pmed.0030267.g003
Figure 3. Direct Cancer Research Spending by Type of Funding Organisation
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the percentage spending by the 15 EU 
member states.
Discussion
Cancer research plays a dominant 
role in two of the EU’s political 
objectives—advancing knowledge in 
health and advancing biotechnology. 
The European Commission has made 
strengthening European research 
a major objective. At the Lisbon 
European Council of March 2000, 
the European Research Area was 
launched—this is an initiative to 
increase the funding and productivity 
of EU research and development. 
Within its framework, the ambitious 
objective was set of increasing research 
spending to 3% of the EU’s GDP by 
2010 [4]. During this period of the 
Sixth Framework Programme (FP6)—
the ﬁ  nancial instrument to help make 
the European Research Area a reality 
(http:⁄⁄www.cordis.lu/fp6/whatisfp6.
htm)—the European Commission 
placed increased emphasis on further 
political commitment by member 
states to research funding and the 
establishment of European frameworks 
through commission funding 
tools. Examples of these tools are 
“networks of excellence”, designed to 
strengthen scientiﬁ  c and technological 
excellence on a particular research 
topic (http:⁄⁄europa.eu.int/comm/
research/fp6/pdf/noe_120503ﬁ  nal.
pdf), and “integrated projects”, an 
“instrument to support objective-
driven research” (http:⁄⁄europa.
eu.int/comm/research/fp6/pdf/
ip_provisions_120503ﬁ  nal.pdf).
Insufﬁ  cient funding of cancer 
research in the EU. However, despite 
the recognition that greater investment 
by the private sector requires more EU 
research to be funded, the FP6 has been 
insufﬁ  cient. Only one in ﬁ  ve fundable 
proposals has been supported, of which 
only 50% of projects judged to be of 
a very high quality were ﬁ  nanced [5]. 
Our survey shows that the FP6 has also 
been inadequate to support the current 
research needs of cancer at a trans-
European level. 
Furthermore, the wide variation in 
available funds for cancer research 
at a member-state level inevitably 
means that the EU funding is not 
complementary but subsidising. Such 
national disparities in cancer research 
funding are particularly pronounced 
in the ten accession countries. Given 
the need for the whole of the enlarged 
EU to engage in the Lisbon agenda, 
the evidence gathered by this survey 
suggests that urgent and speciﬁ  c 
measures are needed to realise the 
potential of these member states. While 
many recommendations have been 
made following the recent review of the 
framework programmes, few of these 
will have any meaningful impact upon 
cancer research without a substantial 
increase in EU funding of cancer 
research [6].
The results of our survey are highly 
relevant to two of the major objectives 
of the EU’s science and technology 
policy—making Europe more attractive 
to the best researchers and improving 
the coordination of national research 
programmes. Cancer research is 
critically dependent on recruiting and 
retaining the brightest minds across 
a very wide spectrum of scientiﬁ  c 
and clinical disciplines. Stimulating 
research funding and creating 
infrastructure or technology platforms 
are irrelevant without the researchers to 
use them. Cancer research, as with most 
biomedical research, needs concerted 
efforts to prevent “brain drain”, as well 
as recruit the ablest students from both 
traditional and nontraditional scientiﬁ  c 
disciplines [7]. Funding for cancer 
research is concentrated at member-
state level, and thus by implication 
so too is most of the funding for 
clinical and nonclinical fellowships. 
This ﬁ  nding, along with data in the 
public domain showing that a number 
of trans-European organisations 
(such as the European Organisation 
for the Research and Treatment of 
Cancer and the European School of 
Oncology) also support a variety of 
fellowships, presents an opportunity 
to review the availability of fellowship 
support, with a view to creating 
additional targeted funding in this 
area through the Seventh Framework 
Programme (FP7)[8]. FP7 is the 
EU’s chief instrument for funding 
scientiﬁ  c research and technological 
DOI: 10.1371/journal.pmed.0030267.g004
Figure 4. Funding By Political Grouping
Current member states are all member states as of May 1, 2004. Accession countries are those 
member states which joined the EU in May 2004, or which are considered “applicant states”. EFTA 
countries include Iceland and Norway. Associate state is Israel.
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development over the period of 2007–
2013 (http:⁄⁄www.cordis.lu/fp7) [8]. 
FP6 has seen resources, through the 
European Research Area Network, 
to network national and regional 
programmes and increase the mutual 
opening up of national and regional 
programmes. The prevailing policy view 
is that research activities are duplicative 
and fragmented. However, our ﬁ  ndings 
suggest otherwise for cancer research. 
Although 138 major funders of cancer 
research were identiﬁ  ed, over 80% 
of the funding is accounted for by 25 
organisations. Furthermore, we found 
no evidence to support any duplication 
of effort in cancer research, although 
such an assessment was not one of the 
primary aims of this survey. 
Even if the 3% of GDP for public 
and private research investment is 
not met by 2010, as is now predicted, 
the framework programme in its next 
iteration (FP7) could nevertheless 
substantially improve cancer research 
and its applications to new therapeutics 
and diagnostics. It could make 
such improvements if, and only if, 
there is a substantial increase in EU 
spending (both at a central level and 
at a member-state level) directed 
speciﬁ  cally at clinical cancer research 
[9]. Furthermore, this increased 
spending at EU level must be tied to a 
more transparent approach to funding 
truly trans-EU cancer research. 
The gap between US and EU funding. 
It has previously been acknowledged 
that the EU fails to match the private 
or public funding levels of the US in 
cancer research and development, but 
just how large the gap has been for 
noncommercial (public) funding has 
not been appreciated until now [10]. 
A survey of cancer research funders, 
similar to our own survey, has been 
undertaken in the US. In 1999 the 
National Cancer Policy Board conducted 
a survey of federal and nonfederal 
sources of cancer research funding 
[11]. The board found, for the ﬁ  scal 
year 1996/1997, that the total amount 
spent on cancer research funding was 
US$5.165 billion.The three major 
contributors were (1) federal funding, 
US$3.060 billion (almost entirely from 
National Cancer Institute); (2) industry 
funding, US$1.6 billion; and (3) funding 
by nonproﬁ  t organisations (e.g., Howard 
Hughes Medical Institute, American 
Cancer Society, Komen Foundation), 
US$305 million. 
This important US survey noted the 
growing contribution of the nonproﬁ  t 
philanthropic sector. The National 
Cancer Policy Board estimated that 
each state also contributed about 
US$200 million per year. This survey 
found a multiplicity of noncommercial 
cancer research funding streams within 
the domains of federal and nonproﬁ  t 
catagories: 20 National Institutes of 
Health, four additional departments 
of the Health and Human Services 
Agencies, a number of additional 
federal agencies, and over eight 
DOI: 10.1371/journal.pmed.0030267.g005
Figure 5. Comparison of Direct Cancer Research Spending between EU-15 Only and the US, 
as a Percentage of GDP and as Spending per Capita
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major foundations and nonproﬁ  t 
organisations, in addition to state 
funding directly to cancer centres, 
e.g., Texas/M. D. Anderson described 
above. In the years following this major 
policy review, US cancer research 
funding grew at a substantial rate. In 
the ﬁ  scal year 2002, the total National 
Cancer Institute obligations alone came 
to US$4.192 billion (this includes both 
intramural and extramural funds), 
representing nearly a doubling of funds 
since 1997 [12].
For a number of reasons, our own 
survey may have underestimated the 
size of the gap between EU and US 
funding of cancer research. First, 
we excluded the accession countries 
in our comparison between the EU 
and the US. Adding these countries 
to the calculations of spending as 
a percentage of GDP or per capita 
would signiﬁ  cantly increase the 
denominator for the EU without any 
signiﬁ  cant addition to the numerator. 
Second, although there are validated 
2002/2003 spending ﬁ  gures for the 
NCI, American Cancer Society, and 
Department of Defense, all other 
noncommercial US data are drawn 
from the 1997 National Cancer 
Policy Board review. Although the 
signiﬁ  cant noncommercial funders 
have been updated, the ﬁ  gure for 
overall US spending will therefore 
be an underestimate. While these 
important caveats magnify the funding 
gap, they do not change the basic 
message from this survey: the EU is 
massively behind the US in its support 
of noncommercial cancer research. 
The underlying data to this overall 
comparison indicates that the problem 
lies both with a lack of central EU 
funding and with many member states 
failing to adequately support cancer 
researchers in their countries. 
Our ﬁ  nding of a difference in 
cancer research spending between 
the US and the EU is also consistent 
with the generally widening gap in 
spending on research and development 
between the US and the EU, which in 
2002 stood at more than  124 billion 
(US$160 billion) [13]. If the funding 
of noncommercial cancer research 
is also widening, then this has major 
implications both for the ability of the 
EU to reverse the emigration of cancer 
researchers to the US and for the EU’s 
overall commercial attractiveness. 
With such a close correlation between 
research activity and high-quality 
service delivery, spending too little 
on research is also likely to have an 
effect, ultimately on the overall care of 
patients with cancer.
A strong EU noncommercial 
cancer research sector is an integral 
promoter of cancer biotechnology. 
Despite the underperforming 
European biotechnology sector, 
the oncology market worldwide has 
witnessed remarkable growth and is 
poised for even greater growth [14]. 
However, the high attrition rate and 
increasing complexity of developing 
and conducting research into new 
anticancer agents, as well as nondrug 
interventions, diagnostics, and 
predictive and prognostic markers, 
requires strong pan-European networks 
linking major centres. The critical issue 
is the fostering of a European cancer 
research noncommercial oligopoly 
that can tackle the major challenges 
from a variety of approaches. The 
preliminary data indicating that across 
the EU less clinical research is funded 
as a proportion of total spending is 
worrisome and needs to be urgently 
addressed.
Conclusion
While the utility of assessing cancer 
research outputs is widely recognised, 
no studies have focused on the funding 
bodies as a unit of evaluation. By 
identifying the major organisational 
funders of cancer research across 
Europe the European Cancer Research 
Funding Survey will further enable 
high-resolution studies aimed at 
evaluating the research activity and 
impact of funding agencies, particularly 
those in the public sector [15].  
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